- Immutep (IMM) completes 50 per cent of patient enrolment for its TACTI-003 phase IIb trial
- The trial is designed to evaluate Immutep’s first-in-class soluble LAG-3 protein, efti, in combination with KEYTRUDA as first line treatment of recurrent or metastatic head and neck squamous cell carcinoma
- The trial will see 154 patients enrolled across more than 25 centres in Australia, Europe and the US, with full recruitment expected by mid-2023
- Immutep CEO Marc Voigt says the company is excited about efti’s potential to safely deliver superior clinical outcomes
- Immutep shares last traded at 27.5 cents at 10:00am AEDT
Immutep (IMM) has enrolled half of the patients participating in its TACTI-003 phase IIb trial.
The trial was designed to evaluate Immutep’s first-in-class soluble LAG-3 protein, eftilagimod alpha (efti) in combination with anti-PD-1 therapy, KEYTRUDA, as a first line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
According to the company, HNSCC is aggressive and difficult to treat, and has become the sixth most common cancer by incidence worldwide, with 890,000 new cases and 450,000 deaths reported in 2018.
The trial will see 154 patients enrolled across more than 25 centres in Australia, Europe and the US, and full recruitment is expected by mid-2023.
The Independent Data Monitoring Committee (IDMC) for the TACTI-003 trial reviewed initial safety data and recommended continuing the trial with no modifications.
“We are pleased to reach this important milestone and extend our sincere appreciation to our investigators, clinical team, partners, and most importantly patients, that have participated in this study,” CEO of Immutep Marc Voigt said.
“As clinical evidence showing the compelling benefits of combining efti with immune checkpoint therapies such as pembrolizumab continues to grow, we are increasingly excited about efti’s potential to safely deliver superior clinical outcomes and meaningfully expand the population of cancer patients that respond to treatment.”
Immutep shares last traded at 27.5 cents at 10:00am AEDT.